search
Back to results

A Study of TAK-676 as Single Agent and TAK-676 in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Primary Purpose

Solid Neoplasms

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
TAK-676
Pembrolizumab
Platinum
5-fluorouracil
Sponsored by
Takeda
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Solid Neoplasms focused on measuring Drug Therapy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  2. TAK-676 SA (dose escalation Part 1A):

    o With histologically confirmed (cytological diagnosis is acceptable) advanced or metastatic solid tumors that have no standard therapeutic options or are intolerant to these therapies.

  3. TAK-676 in combination with pembrolizumab (dose escalation Part 1B):

    • With histologically confirmed (cytological diagnosis is acceptable) advanced or metastatic solid tumors that have no standard therapeutic options or are intolerant to them, including:
    • Tumors that have relapsed or are refractory to anti-programmed cell death protein 1 (anti-PD-1)/anti-programmed cell death ligand 1 (anti-PD-L1) therapy.
    • Tumors that are naive to anti-PD-1/ anti-PD-L1 therapy.
  4. For expansion phase only:

    • SCCHN (Part 2):

    • Participants with histologically confirmed (cytological diagnosis is acceptable) metastatic or recurrent, unresectable SCCHN that is considered incurable by local therapies. Participants should not have had prior systemic therapy administered in the recurrent or metastatic setting. Systemic therapy which was completed more than 6 months before signing consent if given as part of multimodal treatment of locally advanced disease is allowed.
    • Anatomic subsites to be included are oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, and paranasal sinuses (maxillary, ethmoid, sphenoid, and frontal). The exception to this is nasopharyngeal cancer and salivary gland tumors, which will not be included.
    • Participants with oropharyngeal cancer or tumors arising in the paranasal sinuses (maxillary, ethmoid, sphenoid, and frontal) must agree to provide archival tissue for human papilloma virus (HPV) testing or if known, HPV testing results using CINtec® p16 Histology assay and a 70% cutoff point must be provided. If HPV status was previously tested using this method, no additional testing is required.
    • For Part 2A, tumors must have a combined positive score (CPS) ≥1. For Part 2B, any CPS is eligible.
    • For Part 2B, participants must be eligible to receive treatment with either cisplatin or carboplatin in combination with 5-fluorouracil (5-FU) per the treating physician.
  5. CRC (Part 3):

    • Third-line or later MSI-H/dMMR CRC (Part 3A): Participants with histologically confirmed (cytological diagnosis is acceptable) recurrent locally advanced or metastatic MSI-H/dMMR CRC whose disease has progressed on or following therapy with 1) an anti-PD-1 or PD-L1 antibody (ie, pembrolizumab) and 2) at least one line of combination chemotherapy including a fluoropyrimidine and irinotecan OR oxaliplatin with or without an anti- epidermal growth factor receptor (EGFR) or anti-vascular endothelial growth factor (VEGFR) monoclonal antibody (ie, cetuximab or bevacizumab). MSI-H/dMMR CRC participants must have received at least 6 weeks of prior treatment with an anti-PD-1 or anti-PD-L1 antibody.
    • Third-line MSS/pMMR CRC (Part 3B): Participants with histologically confirmed (cytological diagnosis is acceptable) recurrent locally advanced or metastatic MSS/pMMR CRC whose disease has progressed on or following therapy with 2 different lines of combination chemotherapy, including therapy with a fluoropyrimidine and irinotecan AND therapy with a fluoropyrimidine and oxaliplatin. Both lines of therapy may be given with or without an anti-EGFR or anti-VEGFR monoclonal antibody (ie, cetuximab or bevacizumab). Participants with MSS/pMMR CRC must have progressed on or after combination chemotherapy regimens containing BOTH irinotecan AND oxaliplatin.
    • Participants with MSI-H/dMMR or MSS/pMMR CRC must have MSI/MMR status confirmed by a clinically-approved immunohistochemistry (IHC) and/or polymerase chain reaction (PCR) assay.
    • Participants with MSI-H/dMMR or MSS/pMMR CRC must have been treated with 2 prior lines of therapy in the recurrent locally advanced or metastatic setting.
  6. Adequate bone marrow, renal, hepatic and cardiac functions.
  7. Left ventricular ejection fraction (LVEF) >50%, as measured by echocardiogram or multiple-gated acquisition (MUGA) scan within 4 weeks before receiving the first dose of study drug.
  8. Clinically significant toxic effects of previous therapy have recovered to Grade 1 (per NCI CTCAE Version 5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, and/or autoimmune endocrinopathies with stable endocrine replacement therapy.
  9. In dose escalation Part 1, once peripheral evidence of TAK-676 pharmacodynamic stimulation of the innate and/or adaptive immune system is observed in the blood and/or clinical response/partial response (CR/PR) is observed in at least 1 participant, subsequent participants must:

    • Have at least 1 lesion amenable for biopsy.
    • Agree to have 2 tumor biopsies: 1 during the screening period and 1 while on TAK-676 treatment.
  10. Must have at least 1 RECIST v.1.1-evaluable (measurable) lesion. For the dose escalation phase (Part 1) only, nonmeasurable only disease is acceptable.
  11. Pharmacokinetic (PK)/pharmacodynamic blood must be drawn on a peripherally-inserted catheter. TAK-676 is preferentially administered through a central line, but peripheral infusion is acceptable. If a peripheral line is used for TAK-676 and/or pembrolizumab infusion, it must be separate than the one used for PK/pharmacodynamic collection.

Exclusion Criteria:

  1. Corrected QT interval by Fredericia (QTcF) greater than (>) 450 milliseconds (men) or >475 milliseconds (women) on a 12-lead electrocardiogram (ECG) during the screening period.
  2. Grade greater than or equal to (>=) 2 hypotension (that is, hypotension for which nonurgent intervention is required) at screening or during Cycle 1 Day 1 (C1D1) predose assessment.
  3. Oxygen saturation less than (<) 92 percent (%) on room air at screening or during C1D1 predose assessment.
  4. Treated with other STING agonists/antagonist and toll-like receptors agonists within the past 6 months.
  5. Active vaping within 90 days of C1D1 of study drug(s).
  6. Active smoking.
  7. Current history of pneumonitis, interstitial lung disease, severe chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, other restrictive lung diseases, acute pulmonary embolism, or Grade >=2 pleural effusion or ascites not controlled by tap or requiring indwelling catheters.
  8. History of brain metastasis unless:

    • Clinically stable (that is, >=6 weeks) after prior surgery, whole-brain radiation, or stereotactic radiosurgery, AND
    • Off corticosteroids.
  9. Ongoing Grade >= 2 infection or participants with Grade >=2 fever of malignant origin.
  10. Chronic, active hepatitis (example: participants with known hepatitis B surface antigen seropositive and/or detectable hepatitis C virus [HCV]-RNA).
  11. For participants in the dose escalation SA Part 1A only: refusal of standard therapeutic options.
  12. For participants receiving pembrolizumab only: contraindication and/or intolerance to the administration of pembrolizumab.
  13. For participants receiving chemotherapy in Part 2B: contraindication and/or intolerance to the administration of both platinum agents (cisplatin and carboplatin) and/or 5-FU.
  14. Concurrent chemotherapy (except for Part 2B), immunotherapy (except for pembrolizumab in Part 1B, Part 2, and Part 3), biologic, or hormonal therapy (except for adjuvant endocrine therapy for a history of breast cancer). Concurrent use of hormones for noncancer-related conditions is acceptable (except for corticosteroid hormones), unless allowed per exclusion criterion 16.
  15. Radiation therapy within 14 days (42 days for radiation to the lungs) and/or systemic treatment with radionuclides within 42 days before C1D1 of study drug(s). Participants with clinically relevant ongoing pulmonary complications from prior radiation therapy are not eligible.
  16. Use of systemic corticosteroids or other immunosuppressive therapy, concurrently or within 7 days of C1D1 of study drug(s), with the following exceptions:

    • Topical, intranasal, inhaled, ocular, intra-articular, and/or other non-systemic corticosteroids.
    • Physiological doses of replacement steroid therapy (example: for adrenal insufficiency).
    • For participants enrolled in Part 2B, chemotherapy premedication with steroids can be administered according to local standards of care practice.
  17. Use of medications that are known clinical organic anion-transporting polypeptide B1 (OATP1B1) and/or OATP1B3 inhibitors, concurrently or within 14 days of C1D1 of study drug(s).
  18. Receipt of live attenuated vaccine (eg, tuberculosis Bacillus Calmette-Guerin vaccine, oral polio vaccine, measles, rotavirus, yellow fever) within 28 days of C1D1 of study drug(s).
  19. Recipients of allogeneic or autologous stem cell transplantation or organ transplantation.

Sites / Locations

  • University of California San Diego Moores Cancer CenterRecruiting
  • Norris Comprehensive Cancer CenterRecruiting
  • UCI Health - Chao Family Comprehensive Cancer Center
  • University of California Los Angeles - Jonsson Comprehensive Cancer CenterRecruiting
  • SCRI - HealthOne DenverRecruiting
  • Yale Cancer CenterRecruiting
  • Orlando Health Cancer Institute
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
  • University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
  • Massachusetts General HospitalRecruiting
  • Dana-Farber Cancer Institute
  • Barbara Ann Karmanos Cancer Institute - Lawrence and Idell Weisberg Cancer Treatment CenterRecruiting
  • Washington University School of Medicine Siteman Cancer Center
  • University of Cincinnati Health Barrett Cancer CenterRecruiting
  • Providence Portland Medical CenterRecruiting
  • Fox Chase Cancer CenterRecruiting
  • University of Pittsburgh Medical Center (UPMC) Hillman Cancer CenterRecruiting
  • Sarah Cannon Research Institute (SCRI)
  • Mary Crowley Cancer ResearchRecruiting
  • Virginia Cancer Specialists, P.C. - Fairfax
  • Klinikum Wels-GrieskirchenRecruiting
  • Landeskrankenhaus SalzburgRecruiting
  • Landesklinikum Wiener NeustadtRecruiting
  • Universitair Ziekenhuis Antwerpen
  • Universitair Ziekenhuis Leuven - Campus Gasthuisberg
  • Cross Cancer Institute
  • McMaster University Medical Center
  • Princess Margaret Cancer CentreRecruiting
  • Jewish General Hospital
  • McGill University Health Centre
  • LHotel-Dieu de Quebec
  • Beijing Cancer Hospital
  • Sixth Affiliated Hospital of Sun Yat-Sen University/Guangdong Gastrointestinal Hospital
  • West China School of Medicine - West China Hospital of Sichuan University
  • Hopital Foch
  • Institut de Cancerologie de Lorraine
  • Centre Hospitalier Regional et Universitaire de Besancon - Hopital Jean-Minjoz
  • Hopital Saint-Andre
  • Centre Francois Baclesse
  • Centre Georges Francois Leclerc
  • Centre de Lutte contre le Cancer - Centre Oscar Lambret
  • Centre Leon Berard
  • Hopital de la TimoneRecruiting
  • Hopital Saint-AntoineRecruiting
  • Institut de Cancerologie de lOuest - Saint-Herblain - Site Rene GauducheauRecruiting
  • Gustave Roussy
  • Soroka Medical Center
  • Hadassah University Hospital Ein Kerem
  • Tel Aviv Sourasky Medical Center
  • The Chaim Sheba Medical Center
  • National Cancer Center Hospital
  • Centrum Onkologii Im. Prof. F. Lukaszczyka w Bydgoszczy
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy
  • PRCCI Site: Puerto Rico Medical Research Center Torre Medica Hospital Auxilio Mutuo
  • Fundacion de Investigacion de Diego
  • PanOncology Trials: Universidad de Puerto Rico - Centro Comprensivo de Cancer
  • Kantonsspital Sankt Gallen
  • Inselspital Universitatsspital Bern
  • Hopitaux Universitaires de Geneve
  • Centre Hospitalier Universitaire Vaudois Lausanne
  • The Royal Marsden NHS Foundation Trust
  • Queen's University Belfast
  • Leeds Teaching Hospitals NHS Trust
  • University College London Hospitals NHS Foundation TrustRecruiting
  • The Christie NHS Foundation Trust
  • Oxford University Hospitals NHS Foundation TrustRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Part 1 (Monotherapy Dose Escalation Phase): TAK-676 Safety Lead-in + TAK-676 SA [Part 1A]

Part 1B (Combination Dose Escalation Phase): TAK-676 + Pembrolizumab

Japan Safety Lead-in TAK-676 ± Pembrolizumab

Part 2A (SCCHN CPS ≥ 1 Dose Expansion and Optimization Phase): TAK-676 + Pembrolizumab

Part 2B (SCCHN Dose Expansion Phase): TAK-676 + Pembrolizumab + Chemotherapy

Experimental: Part 3A (Expansion Phase in CRC): TAK-676 + Pembrolizumab in MSI-H/dMMR CRC

Part 3B (Expansion and Dose Optimization Phase in CRC): TAK-676 + Pembrolizumab in MSS/pMMR CRC

Arm Description

Safety Lead-in: TAK-676 0.1 mg, infusion, intravenously (IV), once weekly, on Days 1, 8 and 15 in 21-day treatment cycles. TAK-676 single agent (SA) Dose Escalation (Part 1A): TAK-676 SA, infusion, IV, once weekly on Days 1, 8 and 15 in each 21-day treatment cycles with escalating doses (0.2 mg and above). The dosing will be initiated in the TAK-676 SA Dose Escalation Phase based on the available safety and tolerability data from the Safety Lead-in.

TAK-676 escalating doses (0.2 mg and above) in combination with pembrolizumab 200 mg, infusion, IV, once weekly on Days 1, 8 and 15 in each 21-day treatment cycle. Pembrolizumab 200 mg will be administered 1 hour prior to TAK-676 once every 3 weeks (Q3W). The dosing will be initiated when at least two dose levels (DLs) of Part 1A have been evaluated.

TAK-676 5.0 mg, infusion, IV, once on Day 1 in Cycle 0 (cycle length=7 days) in Japanese participants with advanced or metastatic solid tumors. Following the 7-day Cycle 0, participants who do not develop any DLT in Cycle 0 will be administered TAK-676 on Days 1, 8, and 15 of a 21-day cycle in combination with pembrolizumab administered Q3W, IV, in Cycle 1. If no DLTs are observed, study treatment will start with TAK-676 in combination with pembrolizumab administered on Day 1 of each 21-day treatment cycle. Additional dose levels of TAK-676 (such as 3.5 mg or 7.0 mg and higher) in combination with pembrolizumab (200 mg, Q3W) may be explored in the Safety Lead in.

TAK-676 infusion, IV, will be administered in participants with squamous cell carcinoma of head and neck (SCCHN) at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle along with pembrolizumab 200 mg infusion, IV, Q3W. Dose optimization may be performed in this phase.

TAK-676 infusion, IV, will be administered in participants with SCCHN at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle. Pembrolizumab infusion, IV will be administered at 200 mg Q3W. Platinum-based chemotherapy comprising the combination of carboplatin (target area under the curve of 5 mg/mL/minute[AUC 5]) or cisplatin (100 milligrams per square meter [mg/m^2] Day 1 of each treatment cycle), and 5-fluorouracil ([5-FU]; 1000 mg/m^2 per day for 4 consecutive days) every 3 weeks for up to 6 cycles.

TAK-676, infusion, IV, will be administered in participants with microsatellite instability-high /mismatch repair deficient (MSI-H/dMMR) colorectal cancer (CRC) at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle along with pembrolizumab 200 mg infusion, IV, Q3W.

TAK-676, infusion, IV, will be administered in participants with microsatellite stable/mismatch repair proficient (MSS/pMMR) CRC at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle. along with pembrolizumab 200 mg infusion, IV, Q3W. Dose optimization may be performed in this phase.

Outcomes

Primary Outcome Measures

Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity
A severity grade is defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0. Grade 1 scales as Mild (asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 scales as Moderate (minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living [ADL]); Grade 3 scales as Severe (severe or medically significant but not immediately life threatening hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL); Grade 4 scales as Life-threatening consequences, urgent intervention indicated, and Grade 5 scales as Death related to Adverse Event (AE).
Number of Participants with Dose-Limiting Toxicities (DLTs)
A DLT will be defined as any of the TEAEs, but not limited to, those that occur during Cycle 1 and are considered by the investigator to be at least possibly related to TAK-676 as a single agent (SA) or in combination with pembrolizumab. TEAEs meeting DLT definitions occurring in Cycle 2 or later will be considered in the determination of the RDE of TAK-676, both in the TAK-676 SA and the combination with pembrolizumab arms. Toxicity will be evaluated according to NCI CTCAE version 5.0.
Number of Participants Reporting One or More Treatment Emergent Serious Adverse Event (SAEs)
Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations

Secondary Outcome Measures

Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cmax: Maximum Observed Plasma Concentration for TAK-676
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-676
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for TAK-676
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: AUCinf: Area Under the Concentration-time Curve From Time 0 to Infinity for TAK-676
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: t1/2z: Terminal Disposition Phase Half-life for TAK-676
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: CL: Total Clearance After Intravenous Administration for TAK-676
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-676
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: CLR: Renal Clearance for TAK-676
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Percentage of Dose Excreted in Urine During 24 Hours After Dosing
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: CLR/CL%: Renal Clearance as Percentage of Total Clearance for TAK-676
Dose Escalation Phase: Percentage of Dose Excreted in Feces During 24 Hours After Dosing
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Overall Response Rate (ORR)
ORR is defined as the percentage of participants who achieve confirmed complete response (cCR) + confirmed partial response (cPR) during the study in response-evaluable population. ORR will be assessed based on Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1.
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Disease Control Rate (DCR)
DCR is defined as the percentage of participants who achieve cCR + cPR + stable disease (SD) greater than (>) 6 weeks during the study in response-evaluable population. The DCR will be assessed based on RECIST version 1.1.
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Duration of Response (DOR)
DOR is the time from the date of first documentation of a cPR or better to the date of first documentation of progressive disease for responders (cPR or better). Responders without documentation of progressive disease will be censored at the date of last response assessment that is SD or better. DOR will be assessed based on RECIST version 1.1.
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Time to Response (TTR)
TTR is defined as the time from the date of first dose administration to the date of first documented cPR or better by the investigator. TTR will be assessed based on RECIST version 1.1.
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Fold Change from Baseline in Upregulation of TAK-676-induced Stimulator of Interferon Genes (STING)
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Fold Change from Baseline in T-cell Infiltration Upon TAK-676 Treatment
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Fold Change from Baseline of Genomic, Transcriptomic and Protein Expressions in Tumor Tissues
Expansion Phase Only: Progression-Free Survival (PFS)
PFS is defined as the time from the date of first dose administration to the date of first documented disease progression or death due to any cause, whichever occurs first.
Expansion Phase Only: Overall Survival (OS)
OS is defined as the time from the date of first dose administration to the date of death.
Expansion Phase Only: OS Rate at 12 Months
12-month OS rate is defined as the percentage of participants who are still alive at 12 months from their first dose administration.
Expansion Phase Only: OS Rate at 6 Months
6-month OS rate is defined as the percentage of participants who are still alive at 6 months from their first dose administration.

Full Information

First Posted
June 4, 2020
Last Updated
October 23, 2023
Sponsor
Takeda
search

1. Study Identification

Unique Protocol Identification Number
NCT04420884
Brief Title
A Study of TAK-676 as Single Agent and TAK-676 in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Official Title
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 22, 2020 (Actual)
Primary Completion Date
October 19, 2025 (Anticipated)
Study Completion Date
October 19, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Takeda

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The main aim of this study is to check if people with advanced solid tumors have side effects from TAK-676, and to check how much TAK-676 they can receive without getting significant side effects from it when given alone and in combination with pembrolizumab. The study will be conducted in two phases including a dose escalation phase and a dose expansion phase. In the dose escalation phase, escalating doses of TAK-676 are being tested alone and in combination with pembrolizumab to treat participants who have advanced or metastatic solid tumors. In the dose expansion phase, TAK-676 will be studied with pembrolizumab with or without chemotherapy in participants with untreated metastatic or recurrent, unresectable squamous cell carcinoma of head and neck (SCCHN) and in combination with pembrolizumab in third-line or later recurrent locally advanced or metastatic microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and third-line recurrent locally advanced or metastatic microsatellite stable/mismatch repair proficient (MSS/pMMR) colorectal cancer (CRC).
Detailed Description
The drug being tested in this study is called TAK-676. TAK-676 is being tested to treat people who have advanced or metastatic solid tumors. The study will enroll approximately 368 participants. Part 1 consists of an initial Safety Lead-in to Dose Escalation Phase; Part 2 and Part 3 compose the Expansion Phase in 2 specific indications namely, previously untreated metastatic or recurrent, unresectable SCCHN (Part 2) and third-line or later recurrent locally advanced or metastatic MSI-H/dMMR and third-line recurrent locally advanced or metastatic MSS/pMMR CRC (Part 3). Participants will be assigned to the following treatment groups in the respective Phases of the study: Part 1 (Dose Escalation Phase): Safety Lead-in + TAK-676 single agent (SA) [Part 1A] TAK-676 0.1 milligram (mg) in the Safety Lead-in followed by TAK-676 as escalating doses (0.2 mg and above) in Part 1A Part 1B (Combination Dose Escalation Phase): TAK-676 as escalating doses (0.2 mg and above) + Pembrolizumab Japan Safety Lead-in: TAK-676 SA 5.0 mg in the Safety Lead-in+ Pembrolizumab. Additional dose levels of TAK-676 (such as 3.5 mg or 7.0 mg and higher) in combination with pembrolizumab may be explored during the Japan safety lead-in considering recommended dose for expansion (RDE) and dose optimization Once a safe and effective dose is recommended from Part 1, participants of select advanced or metastatic solid tumors will receive TAK-676 in below defined cohorts in the expansion phase: Part 2A (SCCHN Combined Positive Score [CPS] ≥ 1 Dose Expansion Phase): TAK-676 + Pembrolizumab* Part 2B (SCCHN Dose Expansion Phase): TAK-676 + Pembrolizumab + Chemotherapy Part 3A (Expansion Phase in CRC): TAK-676 + Pembrolizumab in MSI-H/dMMR CRC Part 3B (Expansion Phase in CRC): TAK-676 + Pembrolizumab in MSS/pMMR CRC* *Dose optimization will be performed in either Part 2A SCCHN or Part 3B CRC. This multi-center trial will be conducted worldwide. The overall time to participate in this study is 54 months. Participants will make multiple visits to the clinic, including 30 days after last dose of study drug for a follow-up assessment. Participants in Parts 2 and 3 will be followed for survival for up to 12 months after the last dose of study drug.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Neoplasms
Keywords
Drug Therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
368 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part 1 (Monotherapy Dose Escalation Phase): TAK-676 Safety Lead-in + TAK-676 SA [Part 1A]
Arm Type
Experimental
Arm Description
Safety Lead-in: TAK-676 0.1 mg, infusion, intravenously (IV), once weekly, on Days 1, 8 and 15 in 21-day treatment cycles. TAK-676 single agent (SA) Dose Escalation (Part 1A): TAK-676 SA, infusion, IV, once weekly on Days 1, 8 and 15 in each 21-day treatment cycles with escalating doses (0.2 mg and above). The dosing will be initiated in the TAK-676 SA Dose Escalation Phase based on the available safety and tolerability data from the Safety Lead-in.
Arm Title
Part 1B (Combination Dose Escalation Phase): TAK-676 + Pembrolizumab
Arm Type
Experimental
Arm Description
TAK-676 escalating doses (0.2 mg and above) in combination with pembrolizumab 200 mg, infusion, IV, once weekly on Days 1, 8 and 15 in each 21-day treatment cycle. Pembrolizumab 200 mg will be administered 1 hour prior to TAK-676 once every 3 weeks (Q3W). The dosing will be initiated when at least two dose levels (DLs) of Part 1A have been evaluated.
Arm Title
Japan Safety Lead-in TAK-676 ± Pembrolizumab
Arm Type
Experimental
Arm Description
TAK-676 5.0 mg, infusion, IV, once on Day 1 in Cycle 0 (cycle length=7 days) in Japanese participants with advanced or metastatic solid tumors. Following the 7-day Cycle 0, participants who do not develop any DLT in Cycle 0 will be administered TAK-676 on Days 1, 8, and 15 of a 21-day cycle in combination with pembrolizumab administered Q3W, IV, in Cycle 1. If no DLTs are observed, study treatment will start with TAK-676 in combination with pembrolizumab administered on Day 1 of each 21-day treatment cycle. Additional dose levels of TAK-676 (such as 3.5 mg or 7.0 mg and higher) in combination with pembrolizumab (200 mg, Q3W) may be explored in the Safety Lead in.
Arm Title
Part 2A (SCCHN CPS ≥ 1 Dose Expansion and Optimization Phase): TAK-676 + Pembrolizumab
Arm Type
Experimental
Arm Description
TAK-676 infusion, IV, will be administered in participants with squamous cell carcinoma of head and neck (SCCHN) at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle along with pembrolizumab 200 mg infusion, IV, Q3W. Dose optimization may be performed in this phase.
Arm Title
Part 2B (SCCHN Dose Expansion Phase): TAK-676 + Pembrolizumab + Chemotherapy
Arm Type
Experimental
Arm Description
TAK-676 infusion, IV, will be administered in participants with SCCHN at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle. Pembrolizumab infusion, IV will be administered at 200 mg Q3W. Platinum-based chemotherapy comprising the combination of carboplatin (target area under the curve of 5 mg/mL/minute[AUC 5]) or cisplatin (100 milligrams per square meter [mg/m^2] Day 1 of each treatment cycle), and 5-fluorouracil ([5-FU]; 1000 mg/m^2 per day for 4 consecutive days) every 3 weeks for up to 6 cycles.
Arm Title
Experimental: Part 3A (Expansion Phase in CRC): TAK-676 + Pembrolizumab in MSI-H/dMMR CRC
Arm Type
Experimental
Arm Description
TAK-676, infusion, IV, will be administered in participants with microsatellite instability-high /mismatch repair deficient (MSI-H/dMMR) colorectal cancer (CRC) at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle along with pembrolizumab 200 mg infusion, IV, Q3W.
Arm Title
Part 3B (Expansion and Dose Optimization Phase in CRC): TAK-676 + Pembrolizumab in MSS/pMMR CRC
Arm Type
Experimental
Arm Description
TAK-676, infusion, IV, will be administered in participants with microsatellite stable/mismatch repair proficient (MSS/pMMR) CRC at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle. along with pembrolizumab 200 mg infusion, IV, Q3W. Dose optimization may be performed in this phase.
Intervention Type
Drug
Intervention Name(s)
TAK-676
Intervention Description
TAK-676 intravenous Infusion.
Intervention Type
Drug
Intervention Name(s)
Pembrolizumab
Intervention Description
Pembrolizumab intravenous Infusion.
Intervention Type
Drug
Intervention Name(s)
Platinum
Intervention Description
Carboplatin or Cisplatin intravenous infusion
Intervention Type
Drug
Intervention Name(s)
5-fluorouracil
Intervention Description
5-fluorouracil intravenous infusion
Primary Outcome Measure Information:
Title
Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity
Description
A severity grade is defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0. Grade 1 scales as Mild (asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 scales as Moderate (minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living [ADL]); Grade 3 scales as Severe (severe or medically significant but not immediately life threatening hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL); Grade 4 scales as Life-threatening consequences, urgent intervention indicated, and Grade 5 scales as Death related to Adverse Event (AE).
Time Frame
Up to approximately 54 months
Title
Number of Participants with Dose-Limiting Toxicities (DLTs)
Description
A DLT will be defined as any of the TEAEs, but not limited to, those that occur during Cycle 1 and are considered by the investigator to be at least possibly related to TAK-676 as a single agent (SA) or in combination with pembrolizumab. TEAEs meeting DLT definitions occurring in Cycle 2 or later will be considered in the determination of the RDE of TAK-676, both in the TAK-676 SA and the combination with pembrolizumab arms. Toxicity will be evaluated according to NCI CTCAE version 5.0.
Time Frame
Up to approximately 54 months
Title
Number of Participants Reporting One or More Treatment Emergent Serious Adverse Event (SAEs)
Time Frame
Up to approximately 54 months
Title
Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations
Time Frame
Up to approximately 54 months
Secondary Outcome Measure Information:
Title
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cmax: Maximum Observed Plasma Concentration for TAK-676
Time Frame
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)
Title
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-676
Time Frame
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)
Title
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for TAK-676
Time Frame
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)
Title
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: AUCinf: Area Under the Concentration-time Curve From Time 0 to Infinity for TAK-676
Time Frame
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)
Title
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: t1/2z: Terminal Disposition Phase Half-life for TAK-676
Time Frame
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)
Title
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: CL: Total Clearance After Intravenous Administration for TAK-676
Time Frame
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)
Title
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-676
Time Frame
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)
Title
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: CLR: Renal Clearance for TAK-676
Time Frame
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)
Title
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Percentage of Dose Excreted in Urine During 24 Hours After Dosing
Time Frame
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)
Title
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: CLR/CL%: Renal Clearance as Percentage of Total Clearance for TAK-676
Time Frame
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)
Title
Dose Escalation Phase: Percentage of Dose Excreted in Feces During 24 Hours After Dosing
Time Frame
Dose Escalation Phase: Cycle 1 Day 1: from start of infusion and at multiple time points (up to 24 hours) post-infusion (Cycle length=21 days)
Title
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Overall Response Rate (ORR)
Description
ORR is defined as the percentage of participants who achieve confirmed complete response (cCR) + confirmed partial response (cPR) during the study in response-evaluable population. ORR will be assessed based on Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1.
Time Frame
Up to approximately 54 months
Title
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Disease Control Rate (DCR)
Description
DCR is defined as the percentage of participants who achieve cCR + cPR + stable disease (SD) greater than (>) 6 weeks during the study in response-evaluable population. The DCR will be assessed based on RECIST version 1.1.
Time Frame
Up to approximately 54 months
Title
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Duration of Response (DOR)
Description
DOR is the time from the date of first documentation of a cPR or better to the date of first documentation of progressive disease for responders (cPR or better). Responders without documentation of progressive disease will be censored at the date of last response assessment that is SD or better. DOR will be assessed based on RECIST version 1.1.
Time Frame
Up to approximately 54 months
Title
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Time to Response (TTR)
Description
TTR is defined as the time from the date of first dose administration to the date of first documented cPR or better by the investigator. TTR will be assessed based on RECIST version 1.1.
Time Frame
Up to approximately 54 months
Title
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Fold Change from Baseline in Upregulation of TAK-676-induced Stimulator of Interferon Genes (STING)
Time Frame
Baseline up to Month 54
Title
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Fold Change from Baseline in T-cell Infiltration Upon TAK-676 Treatment
Time Frame
Baseline up to Month 54
Title
Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Fold Change from Baseline of Genomic, Transcriptomic and Protein Expressions in Tumor Tissues
Time Frame
Baseline up to Month 54
Title
Expansion Phase Only: Progression-Free Survival (PFS)
Description
PFS is defined as the time from the date of first dose administration to the date of first documented disease progression or death due to any cause, whichever occurs first.
Time Frame
Up to approximately 24 months
Title
Expansion Phase Only: Overall Survival (OS)
Description
OS is defined as the time from the date of first dose administration to the date of death.
Time Frame
Up to approximately 24 months
Title
Expansion Phase Only: OS Rate at 12 Months
Description
12-month OS rate is defined as the percentage of participants who are still alive at 12 months from their first dose administration.
Time Frame
Up to 24 months
Title
Expansion Phase Only: OS Rate at 6 Months
Description
6-month OS rate is defined as the percentage of participants who are still alive at 6 months from their first dose administration.
Time Frame
Up to 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. TAK-676 SA (dose escalation Part 1A): o With histologically confirmed (cytological diagnosis is acceptable) advanced or metastatic solid tumors that have no standard therapeutic options or are intolerant to these therapies. TAK-676 in combination with pembrolizumab (dose escalation Parts 1B and Japan safety lead-in): With histologically confirmed (cytological diagnosis is acceptable) advanced or metastatic solid tumors that have no standard therapeutic options or are intolerant to them, including: Tumors that have relapsed or are refractory to anti-programmed cell death ligand protein 1 (anti PD-(L)-1) therapy. Tumors that are naive to anti-PD-(L)-1 therapy. For expansion phase only: SCCHN (Part 2): Participants with histologically confirmed (cytological diagnosis is acceptable) metastatic or recurrent, unresectable SCCHN that is considered incurable by local therapies. Participants should not have had prior systemic therapy administered in the recurrent or metastatic setting. Systemic therapy which was completed more than 6 months before signing consent if given as part of multimodal treatment of locally advanced disease is allowed. Anatomic subsites to be included are oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, and paranasal sinuses (maxillary, ethmoid, sphenoid, and frontal). The exception to this is nasopharyngeal cancer and salivary gland tumors, which will not be included. Participants with oropharyngeal cancer or tumors arising in the paranasal sinuses (maxillary, ethmoid, sphenoid, and frontal) must agree to provide archival tissue for human papilloma virus (HPV) testing or if known, HPV testing results (using CINtec® p16 Histology assay is preferred but not required) and a 70% cutoff point must be provided. Alternatively, archival tissue or a fresh excisional or core needle biopsy (>=2 cores) is required for the determination of HPV status. If HPV status was previously tested using this method (CINtec® p16 Histology assay is preferred but not required), no additional testing is required. For Part 2A, tumors must have a PD-L1 CPS ≥1. Participants must agree to provide fresh tumor biopsy for analysis from a core or excisional biopsy (fine needle aspirate is not sufficient) at screening for PD-L1 CPS assessment by a central laboratory. This specimen may be the diagnostic sample for participants with a new diagnosis of metastatic SCCHN. Participants for whom newly obtained samples cannot be obtained (eg, inaccessible or participant safety concern) may submit an archived specimen only upon agreement from the Sponsor. Archival tissue can be obtained up to 90 days prior to treatment initiation provided there was no other treatment from the time of biopsy until the start of study treatment. For Part 2B, any CPS is eligible but fresh or archival tissue is required for confirmation of CPS status. For Part 2B, participants must be eligible to receive treatment with either cisplatin or carboplatin in combination with 5-fluorouracil (5-FU) per the treating physician. CRC (Part 3): Third-line or later MSI-H/dMMR CRC (Part 3A): Participants with histologically confirmed (cytological diagnosis is acceptable) recurrent locally advanced or metastatic MSI-H/dMMR CRC whose disease has progressed on or following therapy with 1) an anti-PD-1 or PD-L1 antibody (i.e., pembrolizumab) and 2) at least one line of combination chemotherapy including a fluoropyrimidine and irinotecan OR oxaliplatin with or without an anti-epidermal growth factor receptor (EGFR) or anti-vascular endothelial growth factor (VEGFR) monoclonal antibody (i.e., cetuximab or bevacizumab). MSI-H/dMMR CRC participants must have received at least 6 weeks of prior treatment with an anti-PD-(L)-1 antibody. Only one line of anti-PD-(L)-1 is permitted. Third-line MSS/pMMR CRC (Part 3B): Participants with histologically confirmed (cytological diagnosis is acceptable) recurrent locally advanced or metastatic MSS/pMMR CRC whose disease has progressed on or following therapy with 2 different lines of combination chemotherapy, including therapy with a fluoropyrimidine and irinotecan AND therapy with a fluoropyrimidine and oxaliplatin. Both lines of therapy may be given with or without an anti-EGFR or anti-VEGFR monoclonal antibody (i.e., cetuximab or bevacizumab). Participants with MSS/pMMR CRC must have progressed on or after combination chemotherapy regimens containing BOTH irinotecan AND oxaliplatin. Participants with MSI-H/dMMR or MSS/pMMR CRC must have documented MSI/MMR status assessed by a Clinical Laboratory Improvements Amendment-certified (United States [US] Sites or an accredited (outside of the US) local laboratory using immunohistochemistry (IHC) and/or polymerase chain reaction (PCR) or next generation sequencing (NGS) assay. Adequate tumor tissue available for central laboratory confirmation of MSI/MMR status. Note: confirmation of central test positivity is not required before treatment. Participants with MSI-H/dMMR or MSS/pMMR CRC must have been treated with 2 prior lines of therapy in the recurrent locally advanced or metastatic setting. Adequate bone marrow, renal, hepatic and cardiac functions. Left ventricular ejection fraction (LVEF) >50%, as measured by echocardiogram or multiple-gated acquisition (MUGA) scan within 4 weeks before receiving the first dose of study drug. Clinically significant toxic effects of previous therapy have recovered to Grade 1 (per NCI CTCAE Version 5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, and/or autoimmune endocrinopathies with stable endocrine replacement therapy. In dose escalation Part 1, (not applicable for the Japan safety lead-in) once peripheral evidence of TAK-676 pharmacodynamic stimulation of the innate and/or adaptive immune system is observed in the blood and/or an imaging response/partial response (CR/PR) is observed in at least 1 participant, subsequent participants must: Have at least 1 lesion amenable for biopsy. Agree to have 2 tumor biopsies: 1 during the screening period and 1 while on TAK-676 treatment. Must have at least 1 RECIST version 1.1-evaluable (measurable) lesion. For the dose escalation phase (Part 1) only, nonmeasurable only disease is acceptable. Pharmacokinetic (PK)/pharmacodynamic blood must be drawn on a peripherally-inserted catheter. TAK-676 is preferentially administered through a central line, but peripheral infusion is acceptable. If a peripheral line is used for TAK-676 and/or pembrolizumab infusion, it must be separate than the one used for PK/pharmacodynamic collection. Exclusion Criteria: Corrected QT interval by Fredericia (QTcF) greater than (>) 450 milliseconds (men) or >475 milliseconds (women) on a 12-lead electrocardiogram (ECG) during the screening period. Grade greater than or equal to (>=) 2 hypotension (that is, hypotension for which nonurgent intervention is required) at screening or during Cycle 1 Day 1 (C1D1) predose assessment. Oxygen saturation less than (<) 92 percent (%) on room air at screening or during C1D1 predose assessment. Treated with other STING agonists/antagonist and toll-like receptors agonists within the past 6 months. Current history of pneumonitis, interstitial lung disease, severe chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, other restrictive lung diseases, acute pulmonary embolism, or Grade >=2 pleural effusion or ascites not controlled by tap or requiring indwelling catheters. History of brain and leptomeningeal metastasis unless: Brain metastases are clinically and radiologically stable or improved (that is, >=6 weeks) following surgery, whole-brain radiation, or stereotactic radiosurgery, AND Off corticosteroids. Ongoing Grade >= 2 infection or participants with Grade >=2 fever of malignant origin. Chronic, active hepatitis (example: participants with known hepatitis B surface antigen seropositive and/or detectable hepatitis C virus [HCV]-RNA). For participants in the dose escalation SA Part 1A only: refusal of standard therapeutic options. For participants receiving pembrolizumab only: contraindication and/or intolerance to the administration of pembrolizumab. For participants receiving chemotherapy in Part 2B: contraindication and/or intolerance to the administration of both platinum agents (cisplatin and carboplatin) and/or 5-FU. Participant has had any other prior or concurrent malignancy within 2 years prior to enrollment with the following exceptions: adequately treated localized basal cell or squamous cell carcinoma, or curatively treated in situ carcinoma of the cervix or breast. Other exceptions may be considered upon sponsor consultation. Concurrent chemotherapy (except for Part 2B), immunotherapy (except for pembrolizumab in Part 1B, Part 2, and Part 3), biologic, or hormonal therapy (except for adjuvant endocrine therapy for a history of breast cancer). Concurrent use of hormones for noncancer-related conditions is acceptable (except for corticosteroid hormones) unless allowed per exclusion criterion 16. Radiation therapy within 14 days (42 days for radiation to the lungs) and/or systemic treatment with radionuclides within 42 days before C1D1 of study drug(s). Participants with clinically relevant ongoing pulmonary complications from prior radiation therapy are not eligible. Use of systemic corticosteroids or other immunosuppressive therapy, concurrently or within 7 days of C1D1 of study drug(s), with the following exceptions: Topical, intranasal, inhaled, ocular, intra-articular, and/or other non-systemic corticosteroids. Premedications required for computed tomography (CT) or magnetic resonance imaging (MRI) scans. Physiological doses of replacement steroid therapy (example: for adrenal insufficiency). For participants enrolled in Part 2B, chemotherapy premedication with steroids can be administered according to local standards of care practice. Use of medications that are known clinical organic anion-transporting polypeptide B1 (OATP1B1) and/or OATP1B3 inhibitors, concurrently or within 14 days of C1D1 of study drug(s). Receipt of live attenuated vaccine (eg, tuberculosis Bacillus Calmette-Guerin vaccine, oral polio vaccine, measles, rotavirus, yellow fever) within 28 days of C1D1 of study drug(s). Recipients of allogeneic or autologous stem cell transplantation or organ transplantation. For Part 2 SCCHN only: Has progressive disease (PD) within 6 months of completion of curatively intended systemic treatment for locoregionally advanced SCCHN. Has a life expectancy of less than 3 months and/or has rapidly PD (eg, tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 or anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) agent. Participants with known dihydropyrimidine dehydrogenase (DPD) deficiency or thymidine phosphorylase gene (TYMP) mutations (Part 2B only)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Takeda Contact
Phone
+1-877-825-3327
Email
medinfoUS@takeda.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Study Director
Organizational Affiliation
Takeda
Official's Role
Study Director
Facility Information:
Facility Name
University of California San Diego Moores Cancer Center
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
858-657-7000
Email
spatel@ucsd.edu
First Name & Middle Initial & Last Name & Degree
Sandip Patel
Facility Name
Norris Comprehensive Cancer Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90089
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
323-865-3967
Email
lenz@med.usc.edu
First Name & Middle Initial & Last Name & Degree
Heinz-Josef Lenz
Facility Name
UCI Health - Chao Family Comprehensive Cancer Center
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
949-999-2400
Email
rrbanker@hs.uci.edu
First Name & Middle Initial & Last Name & Degree
Rupali Nabar
Facility Name
University of California Los Angeles - Jonsson Comprehensive Cancer Center
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
310-586-2094
Email
zwainberg@mednet.ucla.edu
First Name & Middle Initial & Last Name & Degree
Zev Wainberg
Facility Name
SCRI - HealthOne Denver
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
720-754-2610
Email
gerald.falchook@scresearch.net
First Name & Middle Initial & Last Name & Degree
Gerald Falchook
Facility Name
Yale Cancer Center
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
203-785-3333
Email
patricia.lorusso@yale.edu
First Name & Middle Initial & Last Name & Degree
Patricia LoRusso
Facility Name
Orlando Health Cancer Institute
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
321-841-1147
Email
wasif.saif@orlandohealth.com
First Name & Middle Initial & Last Name & Degree
Wasif Saif
Facility Name
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
312-695-1300
Email
jochen.lorch@nm.org
First Name & Middle Initial & Last Name & Degree
Jochen Lorch
Facility Name
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
410-328-7224
Email
ranee.mehra@umm.edu
First Name & Middle Initial & Last Name & Degree
Ranee Mehra
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
617-724-4000
Email
xgao4@partners.org
First Name & Middle Initial & Last Name & Degree
Xin Gao
Facility Name
Dana-Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
877-442-3324
Email
jacob_sands@dfci.harvard.edu
First Name & Middle Initial & Last Name & Degree
Jacob Sands
Facility Name
Barbara Ann Karmanos Cancer Institute - Lawrence and Idell Weisberg Cancer Treatment Center
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
313-576-8778
Email
sukaria@karmanos.org
First Name & Middle Initial & Last Name & Degree
Ammar Sukari
Facility Name
Washington University School of Medicine Siteman Cancer Center
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
314-747-8475
Email
dadkins@dom.wustl.edu
First Name & Middle Initial & Last Name & Degree
Douglas Adkins
Facility Name
University of Cincinnati Health Barrett Cancer Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
513-558-2361
Email
sohalda@uc.edu
First Name & Middle Initial & Last Name & Degree
Davendra Sohal
Facility Name
Providence Portland Medical Center
City
Portland
State/Province
Oregon
ZIP/Postal Code
97213
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
503-215-5696
Email
rachel.sanborn@providence.org
First Name & Middle Initial & Last Name & Degree
Rachel Sanborn
Facility Name
Fox Chase Cancer Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19111
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
215-214-1676
Email
anthony.olszanski@fccc.edu
First Name & Middle Initial & Last Name & Degree
Anthony Olszanski
Facility Name
University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
773-702-6180
Email
lukejj@upmc.edu
First Name & Middle Initial & Last Name & Degree
Jason Luke
Facility Name
Sarah Cannon Research Institute (SCRI)
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
615-329-7274
Email
meredith.pelster@scri.com
First Name & Middle Initial & Last Name & Degree
Meredith Pelster
Facility Name
Mary Crowley Cancer Research
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
214-658-1994
Email
dorr@marycrowley.org
First Name & Middle Initial & Last Name & Degree
Douglas Orr
Facility Name
Virginia Cancer Specialists, P.C. - Fairfax
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
304-293-4229
Email
mohamad.salkeni@usoncology.com
First Name & Middle Initial & Last Name & Degree
Mohamad Salkeni
Facility Name
Klinikum Wels-Grieskirchen
City
Wels
State/Province
Oberoesterreich
ZIP/Postal Code
4600
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+4372424153451
Email
josef.thaler@klinikum-wegr.at
First Name & Middle Initial & Last Name & Degree
Josef Thaler
Facility Name
Landeskrankenhaus Salzburg
City
Salzburg
ZIP/Postal Code
5020
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
66244822879; 5725525
Ext
+43
Email
r.greil@salk.at
First Name & Middle Initial & Last Name & Degree
Richard Greil
Facility Name
Landesklinikum Wiener Neustadt
City
Wiener Neustadt
ZIP/Postal Code
2700
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+43 262 290 041 2801
Email
birgit.gruenberger@wienerneustadt.lknoe.at
First Name & Middle Initial & Last Name & Degree
Birgit Grunberger
Facility Name
Universitair Ziekenhuis Antwerpen
City
Edegem
ZIP/Postal Code
2650
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+32 3 821 36 46
Email
hans.prenen@uza.be
First Name & Middle Initial & Last Name & Degree
Hans Prenen
Facility Name
Universitair Ziekenhuis Leuven - Campus Gasthuisberg
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+32 1 634 42 18
Email
sabine.tejpar@uzleuven.be
First Name & Middle Initial & Last Name & Degree
Sabine Tejpar
Facility Name
Cross Cancer Institute
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 1Z2
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
7804328221
Email
michael.sawyer@albertahealthservices.ca
First Name & Middle Initial & Last Name & Degree
Michael Sawyer
Facility Name
McMaster University Medical Center
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8N 3Z5
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+33 9055418115
Email
meyersbr@hhsc.ca
First Name & Middle Initial & Last Name & Degree
Brandon Meyers
Facility Name
Princess Margaret Cancer Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
416-946-4534
Email
philippe.bedard@uhn.ca
First Name & Middle Initial & Last Name & Degree
Philippe Bedard
Facility Name
Jewish General Hospital
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3T 1E2
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
514-340-8222 x23460
Email
petr.kavan@mcgill.ca
First Name & Middle Initial & Last Name & Degree
Petr Kavan
Facility Name
McGill University Health Centre
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H4A 3J1
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
514 3985 522
Email
nathaniel.bouganim@mail.mcgill.ca
First Name & Middle Initial & Last Name & Degree
Nathaniel Bouganim
Facility Name
LHotel-Dieu de Quebec
City
Quebec
ZIP/Postal Code
G1R 2J6
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
418-691-5225
Email
olivier.dumas.1@ulaval.ca
First Name & Middle Initial & Last Name & Degree
Olivier Dumas
Facility Name
Beijing Cancer Hospital
City
Beijing
State/Province
Beijing Sheng
ZIP/Postal Code
100142
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+861088196175; +86 10-88121122
Email
lin100@medmail.com.cn
First Name & Middle Initial & Last Name & Degree
Lin Shen
Facility Name
Sixth Affiliated Hospital of Sun Yat-Sen University/Guangdong Gastrointestinal Hospital
City
Guangzhou
State/Province
Guangzhou Sheng
ZIP/Postal Code
510655
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+86 20-38250745
Email
dengyanh@mail.sysu.edu.cn
First Name & Middle Initial & Last Name & Degree
Yan-Hong Deng
Facility Name
West China School of Medicine - West China Hospital of Sichuan University
City
Chengdu
State/Province
Sichuan Sheng
ZIP/Postal Code
610610
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+86 18980601776
Email
qiumeng33@hotmail.com
First Name & Middle Initial & Last Name & Degree
Meng Qiu
Facility Name
Hopital Foch
City
Suresnes
State/Province
Ile-de-France
ZIP/Postal Code
92150
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
240083333; 1462520
Ext
33
Email
jaafar.bennouna@univ-nantes.fr
First Name & Middle Initial & Last Name & Degree
Jaafar Bennouna-Louridi
Facility Name
Institut de Cancerologie de Lorraine
City
Vandœuvre-lès-Nancy
State/Province
Meurthe-et-Moselle
ZIP/Postal Code
54519
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+33 03 83 59 84 87
Email
c.gavoille@nancy.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Celine Gavoille
Facility Name
Centre Hospitalier Regional et Universitaire de Besancon - Hopital Jean-Minjoz
City
Besancon
ZIP/Postal Code
25000
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
381668166; 381479999
Ext
+33
Email
christophe.borg@efs.sante.fr
First Name & Middle Initial & Last Name & Degree
Christophe Borg
Facility Name
Hopital Saint-Andre
City
Bordeaux
ZIP/Postal Code
33000
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+33556795808
Email
amaury.daste@chu-bordeaux.fr
First Name & Middle Initial & Last Name & Degree
Amaury Daste
Facility Name
Centre Francois Baclesse
City
Caen
ZIP/Postal Code
14000
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+33 2 31 45 50 02
Email
m.dossantos@baclesse.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Melanie Dos Santos
Facility Name
Centre Georges Francois Leclerc
City
Dijon
ZIP/Postal Code
21079
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
380737506; 38039335
Ext
+33
Email
fghiringhelli@cgfl.fr
First Name & Middle Initial & Last Name & Degree
Francois Ghiringhelli
Facility Name
Centre de Lutte contre le Cancer - Centre Oscar Lambret
City
Lille
ZIP/Postal Code
59000
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+33 320 295 954
Email
g-lefebvre@o-lambret.fr
First Name & Middle Initial & Last Name & Degree
Gautier Lefebvre
Facility Name
Centre Leon Berard
City
Lyon
ZIP/Postal Code
69008
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+33478785103
Email
jerome.fayette@lyon.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Jerome Fayette
Facility Name
Hopital de la Timone
City
Marseille
ZIP/Postal Code
13385
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+33491385708
Email
sebastien.salas@ap-hm.fr
First Name & Middle Initial & Last Name & Degree
Sebastien Salas
Facility Name
Hopital Saint-Antoine
City
Paris
ZIP/Postal Code
75012
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+33 149 282 954
Email
thierry.andre@aphp.fr
First Name & Middle Initial & Last Name & Degree
Thierry Andre
Facility Name
Institut de Cancerologie de lOuest - Saint-Herblain - Site Rene Gauducheau
City
St Herblain
ZIP/Postal Code
44805
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+33 01-42-41-28-25
Email
ludovic.doucet@ico.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Ludovic changed to Mallet, Amelie Doucet
Facility Name
Gustave Roussy
City
Villejuif
ZIP/Postal Code
94805
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+33 1 4211 4617
Email
caroline.even@gustaveroussy.fr
First Name & Middle Initial & Last Name & Degree
Caroline Even
Facility Name
Soroka Medical Center
City
Beer Sheva
ZIP/Postal Code
9457108
Country
Israel
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+972 086405407
Email
amichay@clalit.org.il
First Name & Middle Initial & Last Name & Degree
Amichay Meirovitz
Facility Name
Hadassah University Hospital Ein Kerem
City
Jerusalem
ZIP/Postal Code
9112001
Country
Israel
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+972-50-9010225
Email
aron@hadassah.org.il
First Name & Middle Initial & Last Name & Degree
Aron Popovtzer
Facility Name
Tel Aviv Sourasky Medical Center
City
Tel Aviv-Yafo
ZIP/Postal Code
64239
Country
Israel
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+972 36974815; +9723-6394444
Email
ravitg@tlvmc.gov.il
First Name & Middle Initial & Last Name & Degree
Ravit Geva
Facility Name
The Chaim Sheba Medical Center
City
Tel Hashomer
ZIP/Postal Code
52621
Country
Israel
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+972 54 5542707
Email
ronen.stoff@sheba.gov.il
First Name & Middle Initial & Last Name & Degree
Ronen (Beller) Stoff
Facility Name
National Cancer Center Hospital
City
Chuo-Ku
State/Province
Tokyo
ZIP/Postal Code
104-0045
Country
Japan
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+81-3-3542-2511
Email
nbryamam@ncc.go.jp
First Name & Middle Initial & Last Name & Degree
Yamamoto Noboru
Facility Name
Centrum Onkologii Im. Prof. F. Lukaszczyka w Bydgoszczy
City
Bydgoszcz
State/Province
Kujawsko-Pomorskie
ZIP/Postal Code
85-796
Country
Poland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
501446778; 523743208
Ext
+48
Email
bzur@wp.pl
First Name & Middle Initial & Last Name & Degree
Bogdan Zurawski
Facility Name
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy
City
Warsaw
State/Province
Mazowieckie
ZIP/Postal Code
02-034
Country
Poland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+48 506159219; +480225462000
Email
lucjanwyrwicz@gmail.com
First Name & Middle Initial & Last Name & Degree
Lucjan Wyrwicz
Facility Name
PRCCI Site: Puerto Rico Medical Research Center Torre Medica Hospital Auxilio Mutuo
City
San Juan
ZIP/Postal Code
00917
Country
Puerto Rico
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
787-900-5661; 787-296-8394
Email
jlozada@prmedcenter.com
First Name & Middle Initial & Last Name & Degree
Jose Lozada-Costas
Facility Name
Fundacion de Investigacion de Diego
City
San Juan
ZIP/Postal Code
00927
Country
Puerto Rico
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
787-722-1248
Email
macosta@fdipr.com
First Name & Middle Initial & Last Name & Degree
Mirelis Acosta River
Facility Name
PanOncology Trials: Universidad de Puerto Rico - Centro Comprensivo de Cancer
City
San Juan
ZIP/Postal Code
00936
Country
Puerto Rico
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
787-407-3333
Email
maria.garcia@panoncologytrials.com
First Name & Middle Initial & Last Name & Degree
Maria Garcia-Pallas
Facility Name
Kantonsspital Sankt Gallen
City
St. Gallen
State/Province
Saint Gallen
ZIP/Postal Code
9007
Country
Switzerland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+410714942638
Email
dagmar.hess@kssg.ch
First Name & Middle Initial & Last Name & Degree
Dagmar Hess-Mildenberger
Facility Name
Inselspital Universitatsspital Bern
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+41 31 632 41 14
Email
martin.berger@insel.ch
First Name & Middle Initial & Last Name & Degree
Martin D. Berger
Facility Name
Hopitaux Universitaires de Geneve
City
Geneve
ZIP/Postal Code
1205
Country
Switzerland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+41 22-372-33-11
Email
thibaud.kossler@hcuge.ch
First Name & Middle Initial & Last Name & Degree
Thibaud Koessler
Facility Name
Centre Hospitalier Universitaire Vaudois Lausanne
City
Lausanne
ZIP/Postal Code
1011
Country
Switzerland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
41 79 556 76 67
Email
petr.szturz@chuv.ch
First Name & Middle Initial & Last Name & Degree
Petr Szturz
Facility Name
The Royal Marsden NHS Foundation Trust
City
Sutton
State/Province
London
ZIP/Postal Code
SM2 5NG
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
2086613158; 2073528
Ext
+44
Email
david.cunningham@icr.ac.uk
First Name & Middle Initial & Last Name & Degree
David Cunningham
Facility Name
Queen's University Belfast
City
Belfast
State/Province
Northern Ireland
ZIP/Postal Code
BT9 7BL
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+44 289 097 2756
Email
v.coyle@qub.ac.uk
First Name & Middle Initial & Last Name & Degree
Victoria Coyle
Facility Name
Leeds Teaching Hospitals NHS Trust
City
Leeds
ZIP/Postal Code
LS9 7TF
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+44 113-243-3144
Email
f.j.collinson@leeds.ac.uk
First Name & Middle Initial & Last Name & Degree
Fiona Collinson
Facility Name
University College London Hospitals NHS Foundation Trust
City
London
ZIP/Postal Code
NW1 2BU
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+442034477210; +44 2079357700
Email
m.forster@ucl.ac.uk
First Name & Middle Initial & Last Name & Degree
Martin Forster
Facility Name
The Christie NHS Foundation Trust
City
Manchester
ZIP/Postal Code
M20 4BX
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
1614463439; 1614463
Ext
+44
Email
mark.saunders8@nhs.net
First Name & Middle Initial & Last Name & Degree
Mark Saunders
Facility Name
Oxford University Hospitals NHS Foundation Trust
City
Oxford
ZIP/Postal Code
Ox1 2JD
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Contact
Phone
+44 01865 617411
Email
eileen.parkes@oncology.ox.ac.uk
First Name & Middle Initial & Last Name & Degree
Eileen Parkes

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD Sharing Access Criteria
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
IPD Sharing URL
https://vivli.org/ourmember/takeda/
Links:
URL
https://clinicaltrials.takeda.com/study-detail/5f6b603d4db2bf003ab4a3a7
Description
To obtain more information on the study, click here/on this link

Learn more about this trial

A Study of TAK-676 as Single Agent and TAK-676 in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

We'll reach out to this number within 24 hrs